Novavax Ownership
| NVV1 Stock | EUR 5.93 0.04 0.67% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Novavax |
Novavax Stock Ownership Analysis
About 62.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 15.18. Novavax had not issued any dividends in recent years. The entity had 1:20 split on the 10th of May 2019. Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people. To find out more about Novavax contact Stanley Erck at 240 268 2000 or learn more at https://www.novavax.com.Novavax Outstanding Bonds
Novavax issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Novavax uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Novavax bonds can be classified according to their maturity, which is the date when Novavax has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US670001AG19 Corp BondUS670001AG19 | View | |
| US670001AH91 Corp BondUS670001AH91 | View | |
| Novelis Corp 475 Corp BondUS670001AE60 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.